Document Title:

Outcome of Board Meeting - Unaudited Financial Results for Q2 and H1 FY26

Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026 (Q2 FY26)

Nature of Filing / Announcement: Submission of Unaudited Financial Results pursuant to SEBI Listing Regulations

Date of Board Meeting / Approval: November 3, 2026 (Meeting time: 12:00 p.m. to 2:00 p.m.)

Audit Opinion: Clean (Limited Review Report contains no modifications)

Auditor’s Comment: Based on their review, nothing has come to their attention that causes them to believe the Statement contains any material misstatement.

Key Financial Highlights [₹ in crore]

Standalone Results:

Revenue from Operations: Q2 FY26: ₹726.86 crore (Q2 FY25: ₹642.34 crore, +13.2% YoY); H1 FY26: ₹1,380.03 crore (H1 FY25: ₹1,245.39 crore)

Total Income: Q2 FY26: ₹774.19 crore; H1 FY26: ₹1,472.20 crore

Net Profit: Q2 FY26: ₹313.25 crore (Q2 FY25: ₹189.02 crore, +65.7% YoY); H1 FY26: ₹517.72 crore (H1 FY25: ₹380.77 crore)

EPS: Q2 FY26: ₹68.47 (Basic and Diluted); H1 FY26: ₹113.17 (Basic and Diluted)

EPS before Exceptional Items: Q2 FY26: ₹47.09; H1 FY26: ₹91.80

Other Equity: As of September 30, 2026: ₹4,339.66 crore (March 31, 2026: ₹4,157.15 crore)

Cash and Cash Equivalents: As of September 30, 2026: ₹92.82 crore (March 31, 2026: ₹102.66 crore)

Debt: Borrowings (Current): ₹2.50 crore (unchanged from March 31, 2026)

Consolidated Results:

Not Applicable. The Company does not have any subsidiary, associate, or joint venture company.

Segment-wise Performance:

The Company has only one reportable segment, which is 'Pharmaceuticals'. Segment-wise disclosure is not applicable.

Corporate Actions:

Dividend: A final dividend of ₹75 per equity share (face value ₹10 each) (750%) for FY 2025-26 was approved by shareholders at the AGM on July 28, 2026, and paid on August 4, 2026.

Regulatory Disclosures:

The financial results were reviewed by the Audit Committee and approved by the Board.

The results have been prepared in accordance with Ind AS 34 and SEBI LODR Regulations.

The Limited Review Report by the statutory auditors, B S R & Co. LLP, contains no modifications.

Other Significant Information:

Exceptional Items: An amount of ₹132.06 crore (net of related expenses) for Q2/H1 FY26 is disclosed as an exceptional item. This is a non-recurring lump sum payment received from Pfizer Inc. USA consequent to the decision to discontinue the manufacture, marketing, distribution, and sale of Minipress XL effective September 7, 2026.

Referenced Prior Year Exceptional Item: For FY 2025-26, an exceptional charge of ₹49.16 crore was recorded, comprising ₹41.73 crore for personnel separation costs related to a marketing agreement with Cipla Limited and ₹7.43 crore for an increased provision due to the implementation of India's New Labour Codes.

Assets and Liabilities: Total Assets stood at ₹5,292.98 crore as of September 30, 2026 (March 31, 2026: ₹4,921.88 crore). A significant increase was noted in Non-current Lease Liabilities to ₹165.18 crore (March 31, 2026: ₹36.08 crore) and Bank Balances other than cash to ₹3,077.06 crore (March 31, 2026: ₹3,008.10 crore).

Cash Flow: Net cash from operating activities for H1 FY26 was ₹358.99 crore. Net cash used in investing activities was ₹2.80 crore, primarily for the purchase of property, plant and equipment (₹24.44 crore). Net cash used in financing activities was ₹366.03 crore, largely due to dividend payments (₹341.37 crore).